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Abstract
Background: Myelodysplasia syndrome is a heterogeneous group of hematological disorders that are characterized
by abnormal morphology and cytopenias of bone marrow elements. Azacitidine is a hypomethylating agent that is
commonly used in treatment of myelodysplasia syndrome. We present an extremely rare case of cryptogenic
organizing pneumonia following therapy with azacitidine and a review of the relevant literature. This is the fifth
case of azacitidine-induced interstitial lung disease and the sixth one due to hypomethylating drugs; of interest, this
is the first reported case that has occurred after the second cycle. Our case report highlights an important, potentially
treatable and rare side effect of azacitidine and hypomethylating agents in general that might be overlooked by
oncologists. Furthermore, our review of the literature showed heterogeneity in the clinical outcome which might, in
part, be due to delay in initiating corticosteroids treatment.
Case presentation: A 67-year-old white man presented with worsening shortness of breath and mild productive
cough that started 1 week prior to his presentation. An initial chest X-ray showed infiltration of both lung fields.
Radiographic findings of computed axial tomography, results of bronchoscopy and a lung biopsy were consistent with
cryptogenic organizing pneumonia. The patient showed variable clinical response to steroids and he remained
dependent on home oxygen.
Conclusions: We concluded that there is a recognizable potentially life-threatening toxicity due to organizing
pneumonia secondary to azacitidine in the setting of myelodysplasia syndrome treatment. This toxicity is not
limited to the first cycle as in previous cases; furthermore, pleural effusion can be associated with this toxicity.
Health care professionals should be aware of this recognizable side effect. Early recognition and timely
management are critical to prevent permanent lung fibrosis.
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Background
Myelodysplasia syndrome (MDS) is a heterogeneous group
of hematological disorders, which is broadly characterized
by cytopenias, dysmorphic (or abnormally appearing) cel-
lular elements of the bone marrow, and by consequent in-
effective blood cell production. MDS is mostly a disease of
older patients with median age at diagnosis of ≥65 years,
and is characterized by male predominance [1]. Although
onset of the disease earlier than 50 years of age is unusual,
therapy-related MDS is one of the common etiologies in
this age group [2]. Patients with MDS can present with a
wide spectrum of presentations; however, signs and symp-
toms are usually nonspecific. Some of the commonly en-
countered presenting symptoms include fatigue, weakness
and recurrent infections, whereas other cases are diag-
nosed incidentally due to cytopenias in routine blood tests.
Azacitidine is a pyrimidine nucleoside analog that has
been used in treatment of MDS. The mechanism of ac-
tion involves hypomethylation of DNA that results in
increased expression of multiple genes leading to en-
hanced cellular maturation [3]. In this case report, we
intend to report a case of azacitidine-induced interstitial
lung disease (ILD) and to present a review of the rele-
vant literature.
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We were able to identify four similar reported cases
following azacitidine treatment for MDS. Hematologists,
oncologists, and health care professionals should be
aware of the rare but potentially life-threatening toxicity
of azacitidine.
Case presentation
A 67-year-old white man presented with worsening
shortness of breath and mild productive cough that
started approximately 1 week prior to his presentation.
His past medical history was remarkable for type II dia-
betes, hypertension and MDS with excess blast II, with
some fibrosis in his bone marrow, for which he received
two cycles of 5-azacitidine, with the last cycle delivered
2 weeks prior to his presentation. His home medications
included metformin, sitagliptin and bisoprolol. His social
history was significant for 15 pack years of cigarette
smoking.
An initial assessment of his vital signs revealed hyp-
oxia with oxygen saturation of 80 % at room air, heart
rate of 84 beats per minute, and his respiratory rate was
20 per minute. A physical examination was unremark-
able except for bilateral basal fine inspiratory crackles.
Arterial blood gases showed mild respiratory alkalosis.
An initial blood work-up showed hemoglobin of 8.7 g/
dl, platelets count of 30×103/mm3, and white blood cell
(WBC) count of 8.4×103/mm3. Prothrombin time (PT),
partial thromboplastin time (PTT), international nor-
malized ratio (INR), brain natriuretic peptides (BNP),
and kidney and liver function test values were within
normal limits. An electrocardiogram (ECG) and echo-
cardiogram were normal. A chest radiograph showed bi-
lateral interstitial infiltrates.
He was started on dual antibiotics coverage (levofloxa-
cin and piperacillin-tazobactam) for possible pneumonia.
However, on the following day, his oxygen requirement
increased dramatically; he was put on non-invasive ven-
tilation and transferred to an intensive care unit (ICU).
A non-contrast computed tomography (CT) scan of his
chest was done at that time which revealed massive
multifocal bilateral pulmonary consolidations, some of
which were rounded with surrounding ground-glass
opacities, as well as pleural effusion. A wide range of dif-
ferential diagnoses was made at that time, including fun-
gal, viral infection, and bronchiolitis obliterans with
organizing pneumonia (BOOP) (Fig. 1).
Subsequently, his antibiotics were upgraded to caspo-
fungin, teicoplanin, Tamiflu (oseltamivir phosphate),
meropenem, and levofloxacin. A human immunodefi-
ciency virus (HIV) test was performed and was reported
as negative. Bronchoalveolar lavage and left-sided pleural
fluid tapping was performed. Results of the lavage were
negative for aerobic and anaerobic bacterial culture, fun-
gal stain and culture, herpes simplex virus (HSV) and
cytomegalovirus (CMV) polymerase chain reaction
(PCR).
Analysis of his pleural fluid was consistent with a
transudative pattern with a lactate dehydrogenase (LDH)
value of 206 U/L (390 U/L in serum), protein 2.2 g/dl
(5.3 in serum), glucose 210 mg/dl, and WBCs 100 with
90 % lymphocytes. His cytology was negative for malig-
nant cells.
His condition did not improve until he was started on
methylprednisolone 60 mg administered intravenously
twice daily for suspected BOOP. After 7 days of methyl-
prednisolone, his condition improved dramatically and
he was successfully transferred to a general medical
floor; during his stay at the general medical floor his
dose of methylprednisolone was decreased to 40 mg ad-
ministered intravenously twice daily for 4 days, then 20
mg administered intravenously twice daily for 3 days. He
was then discharged home on home oxygen and oral
prednisolone which was slowly tapered over 2 weeks.
A follow-up CT scan was performed 2 weeks later and
showed a variable response in the previously mentioned
multifocal pulmonary consolidations with a background
of pulmonary interstitial thickening and ground-glass
opacification involving both his lungs. Some foci had im-
proved while others had progressed since the previous
examination. In addition, a new opacity appeared on the
lower lobe of his right lung with background interstitial
thickening.
He was readmitted for a CT-guided Tru-Cut biopsy of
the lower lobe of his right lung, which was performed 2
months later; the biopsy showed features of chronic
nonspecific inflammation with macrophages consistent
with organizing pneumonia (Fig. 2).
CMV and HSV immune stains were negative as well as
Giemsa stain for fungal infections.
Fig. 1 Computed tomography scan showing features of interstitial
lung disease
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He was discharged home with oxygen support with a
presumptive diagnosis of drug-induced ILD secondary to
5-azacitidine.
Discussion
Prior to the introduction of hypomethylating agents, in-
cluding azacitidine, as standard therapies for MDS, cyto-
toxic medications were the main stay of treatment.
However, outcomes following these cytotoxic agents
were disappointing. Furthermore, factors related to ad-
vanced age and comorbidities have limited the eligibility
of most patients with MDS for bone marrow transplant-
ation. Azacitidine is a cytidine analog which has a nitro-
gen atom instead of carbon at position five of the
heterocyclic ring. Azacitidine undergoes phosphorylation
to azacitidine triphosphate, which is incorporated into
the ribonucleic acid (RNA), disrupting its metabolism
and protein synthesis. Subsequently, azacitidine diphos-
phate is dephosphorylated into 5-aza-2'-deoxycytidine,
which then undergoes phosphorylation into triphosphate
and then binds to DNA methyltransferase inhibiting its
action. Hypomethylation of CpG island is thought to ac-
company neoplastic transformation and silencing of the
hypermethylated tumor suppressor gene p15INK4B; this
gene is found in MDS and is probably one of the most
important genetic backgrounds in MDS which could be
reversed by azacitidine [4].
Azacitidine has been associated with various adverse
reactions including nausea, pyrexia, diarrhea, fatigue,
cough, dyspnea, and bone marrow suppression which
might result in febrile neutropenia, bleeding, and
anemia. ILD is probably a rare adverse reaction second-
ary to azacitidine. A review of literature identified five
previously reported cases of ILD in association with
hypomethylating agents for treatment of MDS: four were
reported with azacitidine [5–8] and one with decitabine
[9]. We provide descriptions of clinical presentations
and pulmonary outcomes for these reported cases in
Table 1.
In our case the Naranjo scale for adverse drug reaction
was probable [10]. Gemcitabine which is another cytidine
analog has been associated with lung toxicity as well [11].
We have discussed the case of a 67-year-old man di-
agnosed with MDS. He received two cycles of azaciti-
dine administered intravenously (75 mg/m2, which was
150 mg administered intravenously) from days 1 to 7;
he presented with dyspnea 2 weeks following the sec-
ond cycle. His condition deteriorated significantly
despite an early initiation of a wide spectrum of antibi-
otics. Failure to isolate a specific pathogen with bron-
choalveolar lavage, as well as lack of fever, made an
infectious etiology less likely.
Cryptogenic organizing pneumonia (COP) is one of
the ILDs; the disease affects distal bronchioles, alveolar
ducts, and alveoli. Although the pathogenesis is not fully
understood, injury to alveolar epithelial cells in addition
to imbalance between the activity of matrix metallopro-
teinase and its inhibitors seem to be the primary event
that triggers COP. This leads to leakage of intracellular
proteins which triggers an inflammatory reaction with
recruitment of inflammatory cells, followed by produc-
tion of fibromyxoid material resulting in plug formation
against pores of Kohn. A high level of apoptosis is one
of the striking features of this disease which makes it re-
versible in many cases [12, 13].
Our patient developed bilateral migratory lung opaci-
ties which is usually a striking feature of this disease
[14]. The bronchoalveolar lavage as well as the biopsy
failed to identify any specific infectious etiology. The bi-
opsy from the new opacity at the zone of the lower lobe
of his right lung was consistent with COP; 5-azacytidine
was the only recent medication that he had received and
as such it was the most likely culprit.
To the best of our knowledge this is the first case of
azacitidine-induced COP that has occurred after a sec-
ond cycle of azacitidine; our explanation for this was
that our patient either developed a mild COP which was
not apparent clinically or he maintained an immune
Fig. 2 Biopsy which was consistent with cryptogenic organizing pneumonia
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Table 1 Summary of the literature for cases of organizing pneumonia associated with the use of hypomethylating agents
Case report Age/ Gender Presentation Onset Radiographic findings Lung biopsy findings Treatment and outcome
Adams et al. [5] 71-year-old male Shortness of breath
and dyspnea
Immediately after 7-day course
of first cycle of azacitidine
Bilateral perihilar airspace
shadowing
Acute and chronic interstitial and
alveolar fibrosis with chronic
inflammation consistent with
organizing pneumonia
Died few weeks later




granulomatous pattern suggestive of
drug-induced lung disease
Successfully treated with steroids
with resolution of lung infiltrate





Hyperthermia Not clear Acute interstitial pneumonitis
that led to acute respiratory
failure
N/A Responded to high-dose
methylprednisolone
Vasu et al. [9] 65-year-old male Cough, fever, and
chills
2 weeks after initiating
decitabine
Consolidation of lower lobe
of left lung
Patchy areas of organizing pneumonia




Current case 67-year-old male Shortness of breath
and dyspnea





Chronic nonspecific inflammation with
macrophages consistent with
organizing pneumonia
Variable response to steroids.















response which sensitized him to the drug. After expos-
ure to the second cycle these reactions became robust
resulting in severe lung inflammation and damage.
Furthermore this is the first reported case that has been
associated with clinically significant pleural effusion that
required tapping; although it is uncommon, pleural
effusion can be associated with COP. A multicenter
retrospective study of organizing pneumonia showed
that 16 out of 74 patients who had either cryptogenic or
secondary organizing pneumonia had pleural effusion
[15]; de Gispert et al. described pleural effusion in two
out of six patients who had organizing pneumonia [16].
Another retrospective study showed that four out of 18
patients with COP had pleural effusion [17]. The type of
pleural effusion in those reports was not clear. In our
case the patient developed bilateral pleural effusion that
was greater on his left side. The analysis of the pleural
fluid from his left side showed that it was transudative
in nature. All of the following probably account for the
transudative nature of his pleural effusion: the early
lymphatic obstruction secondary to fibrotic changes in
his lungs, the large quantity of intravenously adminis-
tered fluid he received in the ICU as well on the general
medical floor, and the tap that was done approximately
1 week after starting steroids which lessened the inflam-
matory reaction.
To the best of our knowledge, none of our patient’s
regular medications have been associated with lung dis-
ease, although a case report was recently published on
an association between oral hypoglycemic agents and in-
testinal lung disease, particularly metformin and gliben-
clamide [18]. However, our patient has been taking these
drugs for many years, which made it highly unlikely that
they contributed to the ILD.
Conclusions
We concluded that there is a recognizable potentially
life-threatening toxicity due to organizing pneumonia
secondary to azacitidine in the setting of MDS treat-
ment. This toxicity is not limited to the first cycle as in
previous cases; furthermore, pleural effusion can be as-
sociated with this toxicity. Health care professionals
should be aware of such toxicity as early recognition and
timely management are critical to prevent permanent
lung fibrosis.
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